MyeloMATCH MM1YA-CTG01 (Acute Myeloid Leukemia) - Clinical Trial

¿Cuál es el Propósito de este estudio?

We are doing this study to find out if 2 different experimental drug combinations can improve outcomes for people who are newly diagnosed with AML. We want to compare the outcomes from the standard treatment (cytarabine + daunorubicin) to the following experimental regimens:

Venetoclax + cytarabine + daunorubicin
Venetoclax + azacitidine

¿Cuál es la Condición que se está estudiando?

Leucemia mieloide aguda (AML)

¿Quién puede participar en el Estudio?

Adultos de 18 a 59 años que:

Are newly diagnosed with AML
Have not received any previous treatment for AML
Are registered to the Master Screening and Re-Assessment Protocol (myeloMATCH MSRP)

For more information, contact the study team at nick.jeffries@duke.edu.

Grupo etario

Adultos

¿Qué Implica?

If you choose to join this study, you will get a random assignment (random chance) to 1 of 3 groups:

Group 1: venetoclax + cytarabine + daunorubicin (experimental regimen); OR
Group 2: venetoclax + azacitidine (experimental regimen); OR
Group 3: cytarabine + daunorubicin (standard treatment)

Detalles del Estudio

Título Completo

Myelomatch MM1YA-CTG01: A MEASURABLE RESIDUAL DISEASE (MRD) FOCUSED, PHASE II STUDY OF VENETOCLAX PLUS CHEMOTHERAPY FOR NEWLY DIAGNOSED YOUNGER PATIENTS WITH INTERMEDIATE RISK ACUTE MYELOID LEUKEMIA: A TIER 1 MYELOMATCH CLINICAL TRIAL

Investigador Principal